IL6 and head and neck squamous cell carcinoma: We hypothesized that IL-6 would promote cetuximab resistance in HNSCC cells and that inhibiting the IL-6 pathway in a cell line model of acquired cetuximab resistance would restore sensitivity to cetuximab.